Distinguished in Cervical Dysplasia

Wiebren A. Tjalma

Edegem, VLG, BE 
Distinguished in Cervical Dysplasia
Edegem, VLG, BE 
OverviewLocationsClinical Research

Overview

Wiebren Tjalma practices in Edegem, Belgium. Tjalma is rated as a Distinguished expert by MediFind in the treatment of Cervical Dysplasia. Their top areas of expertise are Human Papillomavirus Infection, Cervical Dysplasia, Cervical Cancer, Mastectomy, and Hysterectomy.

Their clinical research consists of co-authoring 156 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 21 articles in the study of Cervical Dysplasia.

Locations

Edegem, VLG 2650, Belgium
Other Locations
Antwerpen, VLG, Belgium
Wilrijk, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options
A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options
Enrollment Status: Completed
Publish Date: March 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

156 Total Publications

Discrepancies between ESTRO/ESGO/SIOPE and NCCN guidelines in the management of vaginal cancer: a call for harmonization.
Discrepancies between ESTRO/ESGO/SIOPE and NCCN guidelines in the management of vaginal cancer: a call for harmonization.
Journal: European journal of obstetrics, gynecology, and reproductive biology
Published: October 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tjalma's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile